CochlearCHEOF 60 Operating Margin % is 16.64% as of Dec. 2025, which is 9% below its 10-year median of 18.24. GuruFocus rates CHEOF with a GF Score™ of 60/100 and a GF Value™ of $219.48 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Cochlear ranks better than 80.15% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Cochlear's Operating Income for the
six
months ended in Dec. 2025 was $129 Mil. Cochlear's Revenue for the
six
months ended in Dec. 2025 was $776 Mil. Therefore, Cochlear's Operating Margin % for the quarter that ended in Dec. 2025 was 16.64%.
Good Sign:
Cochlear Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Cochlear's Operating Margin % or its related term are showing as below:
CHEOF'
s Operating Margin % Range Over the Past 10 Years
Min: 11.34 Med: 18.24 Max: 22.45
Current: 16.43
CHEOF's Operating Margin % is ranked better than 80.15% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.465
vs CHEOF: 16.43
Cochlear's 5-Year Average Operating Margin % Growth Rate was 7.60% per year.
Cochlear's Operating Income for the
six
months ended in Dec. 2025 was $129 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was $253 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Cochlear Operating Margin % Related Terms
Cochlear Operating Margin % Historical Data
* Premium members only.
The historical data trend for Cochlear's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHEOF vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, Cochlear's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cochlear Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Cochlear's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Cochlear's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cochlear (CHEOF) has a Operating Margin % of 16.64% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Cochlear and its competitors. This is near median its historical median of 18.24. Over the past decade, Cochlear's Operating Margin % has ranged from 11.34 to 22.45. According to the industry distribution chart, Cochlear ranks #162 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 19.9%.
Is Cochlear's Operating Margin % too high?
Cochlear's current Operating Margin % of 16.64% is near median its 10-year median of 18.24. Over the past 10 years, this metric has ranged from a low of 11.34 to a high of 22.45. The Medical Devices & Instruments industry median Operating Margin % is 3.47. Cochlear's value of 16.64% is 380.2% above this industry median. Based on the distribution chart, Cochlear ranks #162 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cochlear has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cochlear ranks #162 out of 816 companies for Operating Margin %. This places Cochlear in the top 20% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.47. Cochlear's value of 16.64% is 380.2% above this benchmark. Historically, Cochlear's own Operating Margin % has ranged from 11.34 to 22.45 over the past decade. While the company's 10-year median is 18.24 vs. the industry median of 3.47, Cochlear has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.47, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cochlear's current Operating Margin % of 16.64% is 380.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Cochlear and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cochlear's current Operating Margin % is 16.64%, which is near median its own 10-year median of 18.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (CHEOF) is currently considered Significantly Undervalued. The stock's GF Value™ is $219.48, compared to a current price of $75.55 — trading 65.6% below its estimated fair value. The current Operating Margin % is 16.64%, which is near median its 10-year median of 18.24 and 380.2% above the Medical Devices & Instruments industry median of 3.47. Cochlear's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Cochlear (CHEOF), the current Operating Margin % is 16.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cochlear (CHEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Cochlear stock appears to be undervalued.
The current stock price of $75.55 is trading 65.6% below its estimated GF Value™ of $219.48.
GuruFocus considers Cochlear to be Significantly Undervalued.
Key valuation signals for CHEOF:
Operating Margin %: 16.64% (near median its 10-year median of 18.24)
GF Value™: $219.48 vs. price of $75.55 (65.6% below fair value)
Industry Position: 380.2% above the Medical Devices & Instruments median (#162 of 816)
No single metric tells the full story. See the CHEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
60GF Score
Get the complete analysis for CHEOF
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHEOF has been successfully added to your 
